SI-BONE, Inc. (SIBN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
SI-BONE, Inc. is a medical device company specializing in minimally invasive surgical implant systems for sacroiliac joint dysfunction and pelvic trauma. This report covers the quarterly period ended September 30, 2025. The company operates as a single reporting segment with revenue primarily derived from the United States (95.3% in Q3 2025).
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $48.7 million | $40.3 million | $144.6 million | $118.2 million |
| Gross Profit | $38.8 million | $31.9 million | $115.3 million | $93.3 million |
| Gross Margin | 79.8% | 79.1% | 79.8% | 79.0% |
| Net Loss | $(4.6) million | $(6.6) million | $(17.3) million | $(26.4) million |
| Diluted EPS | $(0.11) | $(0.16) | $(0.40) | $(0.64) |
| Cash & Investments | $145.7 million | $150.0 million (Dec 2024) | As of Sept 30, 2025 | |
| Long-Term Debt | $35.5 million | $35.5 million | Principal: $36.0 million | |
| Operating Cash Flow (9M) | $(2.4) million | $(13.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20.6% in Q3 2025 and 22.3% YTD compared to 2024, driven primarily by increased case volumes in the U.S. due to an expanded product portfolio.
- Expense Increases: Total operating expenses rose 11.9% in Q3 and 9.8% YTD. General and Administrative (G&A) expenses saw the largest increase (23.9% Q3, 24.8% YTD) due to higher personnel costs, stock-based compensation, and legal/consulting fees.
- Improved Loss Profile: Net loss narrowed significantly year-over-year (30.6% reduction in Q3, 34.7% reduction YTD) as revenue growth outpaced expense increases.
- Inventory Build-up: Inventory increased to $35.7 million (from $27.1 million at year-end 2024), reflecting strategic stockpiling for new product introductions.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash and marketable securities ($145.7 million) are sufficient to fund operations for at least the next 12 months. The company has not achieved positive operating cash flow.
- Debt Structure: The company holds a $36.0 million term loan with First-Citizens Bank. The Fourth Amendment (Sept 2025) revised financial covenant periods. Principal repayments begin in 2027, with a maturity date of September 2029.
- Legal Contingency: The company is cooperating with a U.S. Department of Justice investigation regarding the Anti-Kickback Statute and Civil False Claims Act concerning meals and consulting payments to healthcare professionals. The financial impact is currently indeterminable.
- Regulatory & Supply Chain Risks: Risks include potential FDA delays due to government shutdowns or workforce reductions, and supply chain disruptions related to titanium sourcing and sterilization capacity.
- Reimbursement: Uncertainty exists regarding CPT code definitions (27279 vs. 27278) effective January 2026, which could impact reimbursement rates and product demand.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing DOJ investigation.
- Monitor the outcome of CPT code definition changes effective January 1, 2026, and their effect on reimbursement.
- Assess the company's ability to convert inventory build-up into revenue without significant obsolescence.
- Review the specific financial covenants in the Fourth Amended Loan Agreement to ensure continued compliance.
- Track the adoption rates of new products (iFuse INTRA, iFuse TORQ TNT) driving the recent revenue growth.